The Myer logo. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

ASX-listed Premier Investments (ASX:PMV) announced on Monday it has received a merger proposal from Australian national retailer Myer.

Myer would acquire Premier’s apparel brand business (including Just Jeans, Smiggle and Jay Jay’s) in exchange for shares to Premier.

Premier increased its stake in Myer to over 30% in April of this year and Citi analysts noted Premier could ultimately take a controlling stake. The company been incrementally increasing its ownership in Myer in recent history.

That comes in the context of a decline in commercial real estate through COVID as lockdowns changed shopping habits; a post-pandemic cost of living crisis is also rattling (but not drowning) surprisingly resilient consumers.

Notably, the deal includes that Premier no longer owns shares in Myer.

“Premier shareholders would become Myer shareholders directly, whilst also retaining their existing Premier shareholding,” the company wrote on Monday.

Premier Investments, however, want to install chair Solomon Lew on Myer’s board. Shareholders probably won’t mind, given PMV shares are up 52% over the last year.

PMV has already got UBS Securities looking at the deal; in the background, Premier is working to get rid of Smiggle and Peter Alexander.

With that said, Premier wrote “the proposal warrants further consideration” – perhaps not the world’s most enthusiastic language.

PMV last traded at $29.94.

PMV by the numbers
More From The Market Online
Market Close Graphic

ASX Market Close: Another reversal as just-green Oz markets ignore US dive | Jan 3, 2024

The Aussie bourse has defied morning expectations for the second time in as many days, closing out all but flat with a 0.
A Red Sky Energy rig out in the ocean.

Red Sky Energy bleeds more than 18% after ‘landmark’ Angola block entry

Red Sky Energy was ready to pop champagne after being awarded 35% in a "transformative" Angola…
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
A market trading board with ASX marked on the side.

‘Shine a light’: ASX to get more aggressive on companies ‘not up to scratch’ on disclosures

The Australian Securities Exchange (ASX:ASX) will be taking poor disclosure from market-listed companies far more seriously through this next